Definition and Overview
- Cellular adaptation describes the spectrum of reversible, structural and functional changes that cells and tissues undergo in response to altered physiological demands or sublethal injurious stimuli.
- Recognising adaptive changes on histological sections is a core diagnostic skill: they must be distinguished from reactive, dysplastic, and neoplastic processes, and their presence often signals the underlying pathological context.
The four principal adaptive responses are:
- Hypertrophy: increase in cell size without increase in cell number
- Hyperplasia: increase in cell number via proliferation
- Atrophy: decrease in cell size and/or number
- Metaplasia: replacement of one differentiated cell type by another
These responses are not mutually exclusive; hypertrophy and hyperplasia frequently coexist, and metaplasia often develops on a background of atrophy or chronic injury.
Hypertrophy
Definition and Mechanism
- Hypertrophy is an increase in cell volume driven by augmented synthesis of structural proteins and organelles rather than cell division.
- It occurs predominantly in terminally differentiated, post-mitotic cells (cardiomyocytes, skeletal muscle fibres, neurons) that cannot respond to increased demand by dividing.
- The stimulus is typically mechanical stretch or trophic signalling.
- In the heart, pressure overload (systemic hypertension, aortic stenosis) activates stretch-sensitive receptors and downstream pathways including IGF-1/PI3K/AKT and MAPK cascades, upregulating sarcomeric protein genes.
- Hormonal stimuli also drive hypertrophy: physiological uterine enlargement in pregnancy is mediated by oestrogen and mechanical distension.
Morphological Criteria
| Feature | Physiological Hypertrophy | Pathological Hypertrophy |
|---|---|---|
| Cell size | Increased, uniform | Increased, may be irregular |
| Nuclear size | Proportionally enlarged ("boxcar" nuclei in cardiomyocytes) | Enlarged, may show hyperchromasia |
| Nucleoli | Prominent | Prominent |
| Cytoplasm | Abundant, eosinophilic | Abundant; may show vacuolation or loss of myofibrils in late stages |
| Architecture | Preserved | May show disarray (e.g. hypertrophic cardiomyopathy) |
- Cardiac hypertrophy is the paradigm.
- Concentric hypertrophy (pressure overload) shows increased wall thickness with reduced chamber volume; eccentric hypertrophy (volume overload) shows proportional wall and chamber enlargement.
- Histologically, cardiomyocyte diameter exceeds 15-20 µm (normal ~10-15 µm), nuclei are enlarged and hyperchromatic, and interstitial fibrosis accumulates with chronicity.
- Prolonged hypertrophy leads to myofibrillar loss, vacuolation, and eventual myocyte death, culminating in heart failure.
Skeletal muscle hypertrophy (e.g. athletic training) shows increased fibre diameter with peripheral nuclei maintained; fibre type proportions may shift.
Differential Diagnosis at the Microscope
- Hypertrophic cardiomyopathy (HCM): myocyte disarray, interstitial fibrosis, and asymmetric septal hypertrophy; sarcomere gene mutations (MYH7, MYBPC3)
- Storage disorders (glycogen, lipid): cytoplasmic vacuolation mimicking hypertrophy; PAS and Oil Red O stains, electron microscopy
- Rhabdomyoma: large cells with "spider cell" morphology; desmin+, myogenin+
Hyperplasia
Definition and Mechanism
- Hyperplasia is an increase in cell number within a tissue or organ, driven by growth factor signalling that promotes entry of cells into the cell cycle.
- It requires a population capable of division (epithelial cells, fibroblasts, haematopoietic cells) or activation of tissue stem cells.
- Hyperplasia is always a regulated, polyclonal process; loss of this regulation is a hallmark of neoplasia.
- Key signalling pathways include EGF/EGFR, oestrogen receptor (ER) signalling, and WNT/beta-catenin.
- Physiological examples include hepatocyte regeneration after partial hepatectomy and breast acinar proliferation during lactation.
- Pathological examples include endometrial hyperplasia from unopposed oestrogen and prostatic hyperplasia from androgen excess.
Morphological Criteria
- Increased number of morphologically normal or near-normal cells
- Preserved tissue architecture (lobular, glandular, or stratified patterns maintained)
- Mitotic figures present but not atypical
- No significant nuclear pleomorphism or loss of polarity
Endometrial hyperplasia illustrates the spectrum from benign to premalignant:
| WHO Category | Architecture | Cytological Atypia | Malignant Risk |
|---|---|---|---|
| Endometrial hyperplasia without atypia | Crowded glands, cystic change | Absent | <5% |
| Endometrial intraepithelial neoplasia (EIN/atypical hyperplasia) | Back-to-back glands, loss of stroma | Present | ~30% concurrent/subsequent carcinoma |
Prostatic hyperplasia (BPH): nodular proliferation of both glandular and stromal elements in the transition zone; glands lined by two cell layers (luminal columnar + basal), no atypia, no perineural invasion.
Reactive epithelial hyperplasia (e.g. squamous hyperplasia of skin, foveolar hyperplasia in Ménétrier disease): increased cell layers with preserved maturation gradient.
Differential Diagnosis at the Microscope
- Hyperplasia vs. well-differentiated carcinoma: loss of basal cell layer (p63, CK5/6, HMWCK), nuclear atypia, infiltrative growth, perineural invasion
- Endometrial hyperplasia vs. endometrioid carcinoma: stromal invasion, squamous morules, desmoplastic stroma
- Reactive vs. dysplastic: Ki-67 distribution (basal in reactive, full-thickness in dysplasia), p53 pattern
Atrophy
Definition and Mechanism
- Atrophy is a reduction in cell size and/or number resulting from decreased anabolic activity, increased protein catabolism, or cell loss by apoptosis.
- The fundamental cellular mechanism involves reduced protein synthesis combined with accelerated degradation via the ubiquitin-proteasome pathway and autophagy (lysosomal degradation of organelles).
Causes
- Disuse: skeletal muscle atrophy from immobilisation; initially reversible (decreased cell size), later irreversible (decreased cell number via apoptosis)
- Denervation: loss of trophic neural input causes rapid muscle fibre atrophy; type grouping on reinnervation is a diagnostic feature
- Reduced blood supply/ischaemia: cerebral atrophy in atherosclerotic cerebrovascular disease; renal atrophy distal to arterial stenosis
- Inadequate nutrition: generalised wasting; protein-calorie malnutrition
- Loss of endocrine stimulation: endometrial and vaginal atrophy post-menopause (oestrogen withdrawal); prostatic atrophy after androgen deprivation therapy; thyroid atrophy in hypothyroidism
- Pressure: compression by expanding mass lesion causing ischaemic atrophy of adjacent tissue; pancreatic exocrine atrophy from ductal obstruction (e.g. cystic fibrosis, ductal adenocarcinoma)
- Ageing: senile atrophy; lipofuscin accumulation ("brown atrophy" of the heart)
Morphological Criteria
| Feature | Atrophic Tissue |
|---|---|
| Cell size | Reduced |
| Cytoplasm | Scant; may contain lipofuscin granules (golden-brown, PAS+, autofluorescent) |
| Nuclei | Smaller, may be pyknotic |
| Stroma | Relatively increased; fibrosis in chronic atrophy |
| Apoptotic bodies | May be present |
| Architecture | Simplified; glandular atrophy shows reduced gland number and size |
- Denervation atrophy of skeletal muscle: angular atrophic fibres scattered among normal fibres (neurogenic pattern); ATPase histochemistry shows type grouping on reinnervation.
- Contrast with myopathic atrophy (rounded fibres, internal nuclei, fibre splitting).
Pancreatic exocrine atrophy: loss of acinar tissue with relative preservation of islets; fibrofatty replacement; ductal dilation if obstructive.
Endometrial atrophy: thin endometrium with small, inactive glands lined by low columnar to cuboidal epithelium; scant stroma; no mitoses.
Differential Diagnosis at the Microscope
- Atrophic glands vs. adenocarcinoma: atrophic glands retain lobular architecture, two-cell layer (basal cells p63+), no nuclear atypia; carcinoma shows infiltrative single glands, nuclear enlargement, AMACR+, basal cell loss
- Senile cardiac atrophy vs. dilated cardiomyopathy: lipofuscin, reduced myocyte size, no significant fibrosis in pure atrophy
- Neurogenic vs. myopathic atrophy: angular fibres, type grouping (neurogenic) vs. rounded fibres, internal nuclei, necrosis/regeneration (myopathic)
Metaplasia
Definition and Mechanism
- Metaplasia is the reversible replacement of one mature, differentiated cell type by another, typically in response to chronic irritation, inflammation, or altered hormonal milieu.
- The replacing cell type is usually better adapted to the new environmental conditions.
- Metaplasia arises through reprogramming of tissue stem cells rather than transdifferentiation of mature cells; the stem cell adopts a different differentiation pathway.
Metaplasia is not itself premalignant, but the chronic injury that drives it can, if persistent, lead to dysplasia and carcinoma in the metaplastic epithelium.
Squamous Metaplasia
Definition: replacement of non-squamous epithelium (columnar, transitional, or glandular) by stratified squamous epithelium.
Common sites and causes:
| Site | Stimulus | Significance |
|---|---|---|
| Bronchus/bronchioles | Cigarette smoke | Precursor to squamous cell carcinoma; loss of mucociliary function |
| Endocervix (transformation zone) | Acid pH, HPV | Squamocolumnar junction; site of CIN and SCC |
| Endometrium | Chronic inflammation, tamoxifen | Squamous morules in endometrioid lesions; generally benign |
| Urinary bladder | Calculi, chronic catheterisation, schistosomiasis | Keratinising squamous metaplasia: risk of squamous carcinoma |
| Salivary gland ducts | Obstruction, necrotising sialometaplasia | May mimic mucoepidermoid carcinoma |
| Thyroid follicles | Chronic thyroiditis, Hashimoto disease | Benign; distinguish from papillary thyroid carcinoma with squamous features |
| Pancreatic ducts | Ductal obstruction (cystic fibrosis, stones) | Avitaminosis A contributes; benign |
Morphological criteria for squamous metaplasia:
- Stratified squamous epithelium with orderly maturation from basal to superficial layers
- Intercellular bridges (desmosomes) visible on H&E
- No significant nuclear atypia or loss of polarity
- Keratinisation may or may not be present depending on site
- Underlying basement membrane intact
Distinction from squamous dysplasia/carcinoma in situ:
- Dysplasia: nuclear enlargement, hyperchromasia, increased N:C ratio, loss of polarity, atypical mitoses, full-thickness atypia in high-grade
- p16 block positivity (HPV-driven), Ki-67 full-thickness in high-grade CIN
- Invasive SCC: breach of basement membrane, desmoplastic stroma
Glandular (Columnar) Metaplasia
Definition: replacement of squamous or transitional epithelium by glandular/columnar epithelium, or replacement of one glandular type by another (intestinal metaplasia).
- Barrett oesophagus is the prototypic example: chronic gastro-oesophageal reflux damages squamous epithelium, which is replaced by specialised intestinal-type columnar epithelium with goblet cells.
- Diagnostic criteria require endoscopic columnar-lined oesophagus with histological confirmation of goblet cells (Alcian blue pH 2.5 positive).
- Barrett oesophagus carries a 30-40-fold increased risk of oesophageal adenocarcinoma; surveillance biopsies follow the Seattle protocol.
- Intestinal metaplasia of the stomach: replacement of gastric mucosa by intestinal-type epithelium with goblet cells and absorptive cells; complication of chronic Helicobacter pylori gastritis; component of the Correa cascade (normal mucosa → chronic gastritis → atrophy → intestinal metaplasia → dysplasia → adenocarcinoma).
- Complete (type I) vs. incomplete (type II/III) intestinal metaplasia; incomplete type carries higher risk.
Cystitis glandularis: glandular metaplasia of urothelium, typically in the bladder; columnar cells with mucin-secreting goblet cells; associated with chronic inflammation; cystitis glandularis with intestinal metaplasia (florid type) carries low but recognised risk of adenocarcinoma.
Morphological criteria for glandular metaplasia:
- Columnar epithelium with or without goblet cells
- Mucin production (Alcian blue, mucicarmine positive)
- Preserved glandular architecture without back-to-back crowding or stromal invasion
- No significant nuclear atypia
Distinction from adenocarcinoma:
- Metaplasia: preserved architecture, no stromal invasion, no significant atypia, low Ki-67
- Adenocarcinoma: infiltrative glands, desmoplastic stroma, nuclear pleomorphism, loss of surface maturation
Immunohistochemistry in Adaptive Lesions
| Marker | Application | Pattern |
|---|---|---|
| p63 / CK5/6 / HMWCK | Basal cell layer in squamous metaplasia and hyperplasia; loss in carcinoma | Nuclear (p63); cytoplasmic (CK5/6, HMWCK) |
| p16 | Block positivity in HPV-driven dysplasia; patchy in reactive squamous metaplasia | Nuclear + cytoplasmic |
| Ki-67 | Basal/parabasal in reactive; full-thickness in high-grade dysplasia | Nuclear |
| AMACR (P504S) | Positive in prostatic adenocarcinoma; negative in atrophic glands and adenosis | Cytoplasmic granular |
| Alcian blue pH 2.5 | Goblet cell mucin in Barrett oesophagus and intestinal metaplasia | Cytoplasmic |
| CDX2 | Intestinal differentiation in Barrett and gastric intestinal metaplasia | Nuclear |
| Desmin / myogenin | Confirm myogenic lineage in hypertrophic/atrophic muscle | Cytoplasmic (desmin); nuclear (myogenin) |
Exam-Focused Diagnostic Pitfalls
- Atrophic prostate glands can mimic adenocarcinoma: retain basal cells (p63+, HMWCK+), AMACR negative, lobular architecture preserved
- Squamous metaplasia in salivary gland (necrotising sialometaplasia): lobular architecture preserved, no true invasion; can be misdiagnosed as mucoepidermoid carcinoma or SCC
- Squamous morules in endometrial lesions: bland, wirling squamous nests; not evidence of malignancy per se; assess surrounding glandular component for atypia
- Cardiac hypertrophy vs. HCM: HCM requires myocyte disarray (>20% of sampled myocardium), not just increased myocyte diameter; molecular testing for sarcomere mutations
- Denervation atrophy vs. inflammatory myopathy: angular fibres and type grouping favour neurogenic; necrosis, regeneration, and endomysial inflammation favour myopathy; MHC-I upregulation in inflammatory myopathy
- Barrett oesophagus: goblet cells required for diagnosis in most guidelines; cardiac-type mucosa without goblet cells is insufficient; p53 IHC (aberrant: strong block or complete loss) supports dysplasia
Reporting Considerations
When reporting adaptive changes, the synoptic comment should:
- Identify the adaptive change and its morphological basis
- State the likely aetiological context (e.g. "squamous metaplasia consistent with chronic irritation/smoking history")
- Exclude dysplasia and malignancy explicitly, with IHC results if performed
- Recommend clinical correlation or follow-up where the adaptive change carries malignant risk (e.g. Barrett oesophagus surveillance, keratinising squamous metaplasia of bladder)
- For metaplasia in a biopsy context, note whether the sample is adequate to exclude dysplasia
Adaptive changes are reversible if the stimulus is removed; this distinguishes them conceptually from irreversible injury and from neoplasia, and should inform the clinical management recommendation in the report.